Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation & Amortization (CF) (2016 - 2025)

Ptc Therapeutics has reported Depreciation & Amortization (CF) over the past 14 years, most recently at $12.9 million for Q4 2025.

  • Quarterly results put Depreciation & Amortization (CF) at $12.9 million for Q4 2025, up 90.75% from a year ago — trailing twelve months through Dec 2025 was $38.8 million (down 48.7% YoY), and the annual figure for FY2025 was $38.8 million, down 48.7%.
  • Depreciation & Amortization (CF) for Q4 2025 was $12.9 million at Ptc Therapeutics, up from $11.1 million in the prior quarter.
  • Over the last five years, Depreciation & Amortization (CF) for PTCT hit a ceiling of $80.7 million in Q4 2023 and a floor of $6.5 million in Q3 2024.
  • Median Depreciation & Amortization (CF) over the past 5 years was $17.8 million (2021), compared with a mean of $27.2 million.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 107.65% in 2023 and later crashed 91.62% in 2024.
  • Ptc Therapeutics' Depreciation & Amortization (CF) stood at $18.8 million in 2021, then skyrocketed by 106.61% to $38.9 million in 2022, then surged by 107.65% to $80.7 million in 2023, then crashed by 91.62% to $6.8 million in 2024, then surged by 90.75% to $12.9 million in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $12.9 million (Q4 2025), $11.1 million (Q3 2025), and $7.6 million (Q2 2025) per Business Quant data.